Ethics and execution of developing a 2nd wave COVID vaccine - Our interim phase I/II VSV-SARS-CoV2 vaccine experience
Vaccine
.
2021 May 18;39(21):2821-2823.
doi: 10.1016/j.vaccine.2021.04.017.
Epub 2021 Apr 13.
Authors
Yotam Levin
1
,
Noa Madar Balakirski
2
,
Yoseph Caraco
3
,
Eytan Ben-Ami
4
,
Jacob Atsmon
1
,
Hadar Marcus
5
Affiliations
1
Advisor to Israel Institute for Biological Research (IIBR), Nes Ziona, Israel.
2
Israel Institute for Biological Research (IIBR), Nes Ziona, Israel.
3
Hadassah Medical Center, Jerusalem, Israel.
4
Sheba Medical Center, Ramat Gan, Israel.
5
Israel Institute for Biological Research (IIBR), Nes Ziona, Israel. Electronic address: hadarm@iibr.gov.il.
PMID:
33896663
PMCID:
PMC8043614
DOI:
10.1016/j.vaccine.2021.04.017
No abstract available
Publication types
Clinical Trial, Phase I
Clinical Trial, Phase II
MeSH terms
COVID-19 Vaccines
COVID-19*
Humans
RNA, Viral
SARS-CoV-2
Viral Vaccines*
Substances
COVID-19 Vaccines
RNA, Viral
Viral Vaccines